Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1989 1
1990 1
1992 1
1996 1
1997 1
2000 1
2001 2
2002 2
2003 1
2004 2
2005 1
2009 1
2013 1
2014 4
2015 6
2016 3
2017 6
2018 3
2019 3
2020 2
2021 4
2022 2
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. Bartalena L, et al. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479. Eur J Endocrinol. 2021. PMID: 34297684
Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, (b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; (c) …
Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subseque …
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations.
Temple-Oberle C, Shea-Budgell MA, Tan M, Semple JL, Schrag C, Barreto M, Blondeel P, Hamming J, Dayan J, Ljungqvist O; ERAS Society. Temple-Oberle C, et al. Plast Reconstr Surg. 2017 May;139(5):1056e-1071e. doi: 10.1097/PRS.0000000000003242. Plast Reconstr Surg. 2017. PMID: 28445352 Free PMC article. Review.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V....
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V....
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.
Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne JP, Byrne S, Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow M, O'Flynn A, O'Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C, Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R, Gussekloo J; TRUST Study Group. Stott DJ, et al. N Engl J Med. 2017 Jun 29;376(26):2534-2544. doi: 10.1056/NEJMoa1603825. Epub 2017 Apr 3. N Engl J Med. 2017. PMID: 28402245 Free article. Clinical Trial.
Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes.
Hendriks AEJ, Marcovecchio ML, Besser REJ, Bonifacio E, Casteels K, Elding Larsson H, Gemulla G, Lundgren M, Kordonouri O, Mallone R, Pociot F, Szypowska A, Toppari J, Berge TVD, Ziegler AG, Mathieu C, Achenbach P; INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group. Hendriks AEJ, et al. Diabetes Metab Res Rev. 2024 Feb;40(2):e3777. doi: 10.1002/dmrr.3777. Diabetes Metab Res Rev. 2024. PMID: 38375753
Mechanisms of chromium toxicity, carcinogenicity and allergenicity: review of the literature from 1985 to 2000.
Dayan AD, Paine AJ. Dayan AD, et al. Hum Exp Toxicol. 2001 Sep;20(9):439-51. doi: 10.1191/096032701682693062. Hum Exp Toxicol. 2001. PMID: 11776406 Review.
There is good evidence from the clinic and the laboratory that Cr[VI] is the ion responsible for most of the toxic actions, although much of the underlying molecular damage may be due to its intracellular reduction to the even more highly reactive and short-lived chemical species …
There is good evidence from the clinic and the laboratory that Cr[VI] is the ion responsible for most of the toxic actions, although much of …
Insights From Single Cell RNA Sequencing Into the Immunology of Type 1 Diabetes- Cell Phenotypes and Antigen Specificity.
Hanna SJ, Tatovic D, Thayer TC, Dayan CM. Hanna SJ, et al. Front Immunol. 2021 Oct 1;12:751701. doi: 10.3389/fimmu.2021.751701. eCollection 2021. Front Immunol. 2021. PMID: 34659258 Free PMC article. Review.
Single cell sequencing of TCRs has revealed V genes and CDR3 motifs that are commonly used to target islet autoantigens, although truly public TCRs remain elusive. ...
Single cell sequencing of TCRs has revealed V genes and CDR3 motifs that are commonly used to target islet autoantigens, although tru …
Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design.
Premawardhana LD, Taylor PN, Okosieme OE, Adlan MA, Obuobie EK, Dayan CM. Premawardhana LD, et al. Front Endocrinol (Lausanne). 2023 Nov 16;14:1282608. doi: 10.3389/fendo.2023.1282608. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38034018 Free PMC article. Review.
We recommend attention to the following aspects of trial design for future RCTs of LT3 + LT4 compared to LT4 alone: (a) Subject selection-(i) measurable symptoms (disadvantages should be recognized); (ii) using a validated thyroid specific PROM such as ThyPRO39 or the Composite s …
We recommend attention to the following aspects of trial design for future RCTs of LT3 + LT4 compared to LT4 alone: (a) Subject selection-(i …
51 results